Implementation of best medical therapy for cardiovascular risk factors in vascular surgery patients treated in a tertiary referral regional unit

International Journal of Clinical Practice

Volumn 68, Issue 9, 2014, Pages 1100-1109

  McGrogan, D ^a   Mark, D ^a   Lee, B ^a   O'Donnell, M E ^b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; ANGINA PECTORIS; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; FEMALE; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICATION THERAPY MANAGEMENT; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PRESCRIPTION; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; SURGICAL PATIENT; TERTIARY HEALTH CARE; VASCULAR SURGERY; AGED; CARDIOVASCULAR DISEASES; COMPLICATION; HYPERLIPIDEMIAS; MIDDLE AGED; MORTALITY; PRACTICE GUIDELINE; REHABILITATION; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPIRIN; CARDIOVASCULAR DISEASES; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; VASCULAR SURGICAL PROCEDURES;

EID: 84908118461     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12415     Document Type: Article

References (37)

1. Cassar K, Coull R, Bachoo P, Macaulay E, Brittenden J. Management of secondary risk factors in patients with intermittent claudication. Eur J Vasc Endovasc Surg 2003; 26(3): 262-6.
2. Hirsch AT, Criqui MH, Treat-Jacobson D et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286(11): 1317-24.
3. Daskalopoulou SS, Pathmarajah M, Kakkos SK et al. Association between ankle-brachial index and risk factor profile in patients newly diagnosed with intermittent claudication. Circ J 2008; 72(3): 441-8.
4. Perk J, De Backer G, Gohlke H et al.; European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33(13): 1635-701.
5. Sillesen H. What does 'best medical therapy' really mean? Eur J Vasc Endovasc Surg 2008; 35(2): 139-44.
6. Stansby G, Mister R, Fowkes G et al.; Prospective Registry and Evaluation of Peripheral Arterial Risks, Events and Distribution Investigators. High risk of peripheral arterial disease in the United Kingdom: 2-year results of a prospective registry. Angiology 2011; 62(2): 111-8.
7. Moll FL, Powell JT, Fraedrich G et al.; European Society for Vascular Surgery. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. Eur J Vasc Endovasc Surg 2011; 41(Suppl. 1):S1-58.
8. Lindholt JS, Sorensen HT, Michel JB, Thomsen HF, Henneberg EW. Low-dose aspirin may prevent growth and later surgical repair of medium-sized abdominal aortic aneurysms. Vasc Endovascular Surg 2008; 42(4): 329-34.
9. Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. Circulation 2008; 117(14): 1883-9.
10. Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of peripheral vascular disease, 2006. http://www.sign.ac.uk/pdf/sign89.pdf (accessed 27 January 2014).
11. Smith SC Jr, Allen J, Blair SN et al.; AHA/ACC; National Heart, Lung and Blood Institute. AHA/ ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113(19):2363-72.
12. Rice TW, Lumsden AB. Optimal medical management of peripheral arterial disease. Vasc Endovascular Surg 2006; 40(4): 312-27.
13. Paravastu SC, Mendonca DA, da Silva A. Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg 2009; 38(1): 66-70.
14. Liapis CD, Bell PF, Mikhailidis DP et al.; ESVS Guidelines Collaborators; European Society for Vascular Surgery. ESVS Guidelines: section A - prevention in patients with carotid stenosis. Curr Vasc Pharmacol 2010;8(5):673-81.
15. Antithrombotics Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71-86.
16. Dorffler-Melly J, Koopman MM, Adam DJ, Büller HR, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev 2003; (3): CD000535.
17. Review. Update in: Cochrane Database Syst Rev. 2008;(4): CD000535.
18. Scandanavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandanavian Simvastatin Survival Study (4S). Lancet 1994; 135: 1383-9.
19. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335(14): 1001-9.
20. Streja L, Packard CJ, Shepherd J, Cobbe S, Ford I; WOSCOPS Group. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 2002;90(7):731-6.
21. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344 (21): 1608-21.
22. Aikawa M, Sugiyama S, Hill CC et al. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 2002; 106: 1390-6.
23. Andrews TC, Raby K, Barry J et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997; 95: 324-8.
24. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by rho GTPase. J Biol Chem 1998; 273: 24266-71.
25. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 2001; 12: 383-9.
26. Chobanian AV, Bakris GL, Black HR et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206-52.
27. Lonn EM, Yusuf S, Jha P et al. Emerging role of angiotensin- converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90:2056-69.
28. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145-53.
29. British Heart Foundation Health Promotion Research Group. Coronary heart disease statistics. A compendium of health statistics, 2012 edn. http://www.bhf.org.uk/plugins/PublicationsSearch Results/DownloadFile.aspx?docid=508b8b91-1301-4ad7- bc7e-7f413877548b&title=Coronary+Heart+Disease+ Statistics+2012+&resource=G608 (accessed 04 March 2014).
30. Ferket BS, Colkesen EB, Visser JJ et al. Systematic review of guidelines on cardiovascular risk assessment: which recommendations should clinicians follow for a cardiovascular health check? Arch Intern Med 2010; 170(1): 27-40.
31. No authors listed. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997; 18: 1569-82.
32. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16 (2):121-37.
33. Van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patient. N Engl J Med 2001; 345(19): 1359-67.
34. Zerr KJ, Furnary AP, Grunkemeier GL, Bookin S, Kanhere V, Starr A. Glucose control lowers the risk of wound infection in diabetics after open - heart operations. Ann Thorac Surg 1997; 63: 356-61.
35. McCavert M, Mone F, Dooher M, Brown R, O'Donnell ME. Peri-operative blood glucose management in general surgery. A potential element for improved diabetic patient outcomes - an observational cohort study. Int J Surg 2010; 8: 494-8.
36. Jacober SJ, Sowers JR. An update on peri-operative management of diabetes. Arch Int Med 1999; 159 (20): 2405e11.
37. Halkos ME, Lattouf OM, Puskas JD et al. Elevated preoperative hemoglobin A1c level is associated with reduced long-term survival after coronary artery bypass surgery. Ann Thorac Surg 2008; 86(5): 1431-7.